News & Updates
Excerpt from the Press Release: EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 variants, including the South African Variant (B.1.351), in pseudovirus testing. This…
Read More
Excerpt from the Press Release: LEXINGTON, Mass., Feb. 18, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces publication of two pivotal studies that provided the basis for approval of Leukine (sargramostim, yeast-derived rhu GM-CSF) to improve survival in patients exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome…
Read More
Excerpt from the Press Release: OXFORDSHIRE, England and CONSHOHOCKEN, Pa. and ROCKVILLE, Md., Feb. 19, 2021 (GLOBE NEWSWIRE) — Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today…
Read More
Excerpt from the Article: MRI scans reveal myocarditis, scarring, infarction, and ischemia in recovered patients with elevated troponin levels. Roughly 50 percent of patients who recover after being hospitalized with severe COVID-19 suffer heart damage. MRI scans, conducted at least one month post-discharge, show patients who have elevated levels of troponin show evidence of heart…
Read More
Excerpt from the Press Release: Neutralizing antibodies develop within two weeks of a SARS-CoV-2 infection, but their durability and intensity can vary by individual, prompting concerns about the prospects of long-lasting immunity and efficacy of COVID-19 vaccines. In a PLOS ONE paper, published online February 11, 2021, researchers at University of California San Diego School…
Read More
Excerpt from the Article: CT, MRI, and ultrasound images reveal the myriad of ways the virus prompts the body to attack itself – with this knowledge, radiologists can better contribute to treatment planning. Not only does COVID-19 attack the body, but radiology images show that the virus can actually make the body attack itself. For…
Read More
Excerpt from the Press Release: Scientists at Sanford Burnham Prebys Medical Discovery Institute have designed a next-generation drug, called SBP-7455, which holds promise as a treatment for triple-negative breast cancer—an aggressive cancer with limited treatment options. The drug blocks a cellular recycling process called autophagy, which cancer cells hijack as a way to resist treatment.…
Read More
Excerpt from the Press Release: BOSTON, Feb. 08, 2021 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced the publication of new data highlighting the highly potent in vitro antiviral activity of AT-527 against SARS-CoV-2. AT-527 is an orally administered, direct-acting antiviral developmental agent derived from Atea’s purine nucleotide…
Read More
Excerpt from the Article: February 11, 2021 | Messenger RNA (mRNA) vaccines were the focus of a symposium on COVID-19 vaccines held during last week’s COVID-19 and Cancer virtual meeting of the American Association for Cancer Research. To date, only two vaccines have received Emergency Use Authorization by the U.S. Food and Drug Administration and…
Read More
Excerpt from the announcement: Take your first steps toward entrepreneurship with Building a Biotech Venture, a new program for regenerative medicine-focused trainees in labs at the University of Toronto (U of T) and its affiliated hospitals, offered in partnership with the Health Innovation Hub, a campus-linked accelerator at the Temerty Faculty of Medicine at U of T. In the H2i 10…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?